Pazopanib
Uses of Pazopanib
Pazopanib is commonly used to treat renal cell carcinoma and Soft Tissue Sarcoma
How Pazopanib Works
Pazopanib is an inhibitor of receptor tyrosine kinases (RTKs) which are involved in the pathway of malignant cells proliferation resulting in the retardation of tumour growth. RTKs involved in the blockade include receptors for vascular endothelial growth factors, platelet-derived growth factors, and stem cell factor.
Side Effects of Pazopanib
Diarrhea, Hair colour change, Skin hypopigmentation, Exfoliative rash, Increased blood pressure, Nausea, Headache, Fatigue, Loss of appetite, Vomiting, Distortion of the sense of taste, Stomatitis, Weight decreased, Elevated liver enzymes
Warnings
Kidney Use With Care
Pazopanib should be used with caution in patients with mild kidney disease. Dose adjustment of Pazopanib is not needed. Please consult your doctor before using it. Use of Pazopanib in patients with moderate to severe kidney disease is unknown.
Alcohol Limited Data
Certain food and medications will have interactions with concurrent use of Pazopanib but there is no specific data stating so. Please consult your doctor before using it.
Pregnancy Not Safe
Human studies have shown adverse effects on the fetus. However, the benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor before using it.
Driving Generally Safe
Pazopanib cause negligible to no side effects which could affect your ability to concentrate and drive. Do not drive unless you are feeling well.
Liver Limited Data
Pazopanib should be used with caution in patients with mild to moderate liver disease. Dose adjustment of Pazopanib may be needed. Please consult your doctor before using it. Use of Pazopanib is not recommended in patients with severe kidney disease.
Lactation Limited Data
It is unknown whether Pazopanib is excreted into human breast milk and its potential adverse effect on the feeding baby. Please consult your doctor before using it.
Written by Dr Sri Viknarajan, MD (Universiti Hasanuddin, Indonesia)
Reviewed by Dr Nur Syuhada binti Zulkifli, MD, Universiti Kebangsaan Malaysia (UKM).
